Your search for supplemental oxygen returned 22 results

Odds of mortality or discharge to hospice reduced for those receiving supplemental oxygen or mechanical ventilation and/or ECMO

Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity

No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.

The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.

The update was based on data from the COV-BARRIER study.

Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.